Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: IDRA
CUSIP:

Key Metrics:

Previous Close: $2.31
50 Day Moving Average: $2.14
200 Day Moving Average: $1.80
52-Week Range: $1.19 - $4.42
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -5.33
P/E Growth: 0.00
Market Cap: $310.73M
Outstanding Shares: 121,378,000
Beta: 2.78

Profitability:

Net Margins: -6,169.32%
Return on Equity: -64.09%
Return on Assets: -58.44%

Debt:

Debt-to-Equity Ratio: 0.01%
Current Ratio: 9.14%
Quick Ratio: 9.14%

Additional Links:

Companies Related to Idera Pharmaceuticals:

Consensus Ratings for Idera Pharmaceuticals (NASDAQ:IDRA) (?)

Ratings Breakdown:	3 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$6.50 (153.91% upside)

Analysts' Ratings History for Idera Pharmaceuticals (NASDAQ:IDRA)

Show:

Date	Firm	Action	Rating	Price Target
9/26/2016	Wedbush	Reiterated Rating	Outperform	$6.00
5/10/2016	Cowen and Company	Reiterated Rating	Buy
3/12/2016	Piper Jaffray Cos.	Reiterated Rating	Buy
6/15/2015	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$6.00

(Data available from 10/1/2014 forward)

Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/4/2016
8/2/2016	Q216	($0.11)	($0.11)			View	N/A
5/9/2016	Q1	($0.11)	($0.11)			View	Listen
3/10/2016	Q4	($0.11)	($0.10)	$20.00 million		View	N/A
11/6/2015	Q315	($0.11)	($0.10)			View	N/A
8/6/2015	Q215	($0.11)	($0.11)			View	N/A
5/11/2015	Q1	($0.11)	($0.12)	$0.03 million		View	N/A
3/12/2015	Q414	($0.11)	($0.14)	$0.03 million		View	N/A
11/7/2014	Q314	($0.11)	($0.11)			View	Listen
8/12/2014	Q214	($0.09)	($0.10)			View	Listen
5/13/2014	Q114	($0.08)	($0.12)			View	Listen
3/13/2014	Q4	($0.08)	($0.10)			View	Listen
11/14/2013	Q3	($0.11)	($0.11)	$0.03 million	$0.01 million	View	Listen
8/15/2013	Q213	($0.12)	($0.15)			View	N/A
5/15/2013	Q113	($0.19)	($0.15)			View	N/A
3/11/2013	Q4 2012		($0.24)			View	N/A
11/12/2012	Q312		($0.17)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.11)	($0.10)	($0.11)
Q2 2016	1	($0.11)	($0.11)	($0.11)
Q3 2016	2	($0.11)	($0.09)	($0.10)
Q4 2016	1	($0.10)	($0.10)	($0.10)
Q1 2017	1	($0.10)	($0.10)	($0.10)
Q2 2017	1	($0.11)	($0.11)	($0.11)
Q3 2017	1	($0.10)	($0.10)	($0.10)
Q4 2017	1	($0.10)	($0.10)	($0.10)

(Data provided by Zacks Investment Research)

Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Idera Pharmaceuticals (NASDAQ:IDRA)

Insider Ownership Percentage: 29.50%
Institutional Ownership Percentage: 28.44%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/13/2016	James A Geraghty	Director	Buy	10,000	$1.34	$13,400.00
5/12/2016	Mark J Casey	VP	Buy	34,450	$1.44	$49,608.00
3/15/2016	Vincent Milano	CEO	Buy	40,000	$1.97	$78,800.00
2/13/2015	Julian Baker	Director	Buy	5,333,333	$3.75	$19,999,998.75
12/16/2014	Youssef El Zein	Director	Sell	100,000	$3.68	$368,000.00
12/12/2014	Vincent Milano	CEO	Buy	200,000	$4.00	$800,000.00
5/27/2014	James A Geraghty	Director	Buy	10,000	$2.65	$26,500.00
12/6/2013	James A Geraghty	Director	Buy	40,000	$2.72	$108,800.00
9/16/2013	James A Geraghty	Director	Buy	60,000	$1.90	$114,000.00
8/19/2013	James A Geraghty	Director	Buy	300,000	$1.75	$525,000.00
5/7/2013	C Keith Hartley	Director	Buy	90,000	$0.49	$44,100.00

(Data available from 1/1/2013 forward)

Latest Headlines for Idera Pharmaceuticals (NASDAQ:IDRA)

Date	Headline
	The annual Dividend for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is $3 (NASDAQ:IDRA) myhealthbowl.com - September 29 at 5:28 PM
	The annual Dividend for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is $3 (NASDAQ:IDRA) myhealthbowl.com - September 29 at 5:28 PM
	Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has the current quarter growth of -10% - Newburgh Press (NASDAQ:IDRA) newburghpress.com - September 28 at 5:24 PM
	News review of 2 biotech stocks: ImmunoGen, Inc. (NASDAQ:IMGN), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - The Voice Registrar (NASDAQ:IDRA) voiceregistrar.com - September 27 at 5:32 PM
	Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) EPS Analysis - Newburgh Press (NASDAQ:IDRA) newburghpress.com - September 27 at 5:32 PM
	Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Reports Phase 1 Data Showing Encouraging Clinical ... - Smarter Analyst (NASDAQ:IDRA) www.smarteranalyst.com - September 27 at 5:32 PM
	Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Presents New Third Generation Antisense (3GA) Data at ... - Smarter Analyst (NASDAQ:IDRA) www.smarteranalyst.com - September 27 at 5:32 PM
	Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (NASDAQ:IDRA) finance.yahoo.com - September 27 at 10:07 AM
	Idera Pharmaceuticals Inc (NASDAQ:IDRA): Traders Insight’s Pick of The Day, Made 40% In Just One Week (NASDAQ:IDRA) www.marketnewscall.com - September 26 at 5:39 PM
	Idera Pharmaceuticals Reports Promising Data from Ongoing Phase [..] (NASDAQ:IDRA) www.pr-inside.com - September 26 at 10:11 AM
	Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metasta... (NASDAQ:IDRA) www.publicnow.com - September 26 at 10:11 AM
	Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic Melanoma (NASDAQ:IDRA) www.publicnow.com - September 26 at 10:11 AM
	Biotech Stocks Worth a Closer Look: Threshold Pharmaceuticals (NASDAQ:THLD), Idera Pharmaceuticals (NASDAQ ... - The Voice Registrar (NASDAQ:IDRA) voiceregistrar.com - September 25 at 4:58 PM
	Filipino leader curses out European Union over calls to halt drug killings (NASDAQ:IDRA) avauncer.com - September 23 at 8:31 AM
	Active biotech company shares in the news: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Amicus Therapeutics, Inc ... - The Voice Registrar (NASDAQ:IDRA) voiceregistrar.com - September 22 at 3:36 PM
	Hot Biotech Stocks Recap: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Idera Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:IDRA) voiceregistrar.com - September 22 at 3:36 PM
	Biotech news that matter for investors: CoLucid Pharmaceuticals (CLCD), Idera Pharmaceuticals (NASDAQ:IDRA) - The Voice Registrar (NASDAQ:IDRA) voiceregistrar.com - September 21 at 3:48 PM
	Penny Stock Investors Take an Interest in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 21 at 3:48 PM
	Mid-Day Market Update: Tobira Therapeutics Jumps Following Allergan Buyout; HNI Shares Slide - Benzinga (NASDAQ:IDRA) www.benzinga.com - September 21 at 3:48 PM
	Penny Stock Investors Keen on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 21 at 3:48 PM
	Overbuying Activity: Idera Pharmaceuticals Inc (NASDAQ:IDRA) - Post Registrar (NASDAQ:IDRA) postregistrar.com - September 21 at 3:48 PM
	Mid-Day Market Update: Tobira Therapeutics Jumps Following Allergan Buyout; HNI Shares Slide (NASDAQ:IDRA) www.nasdaq.com - September 21 at 9:46 AM
	Idera Pharmaceuticals Inc (NASDAQ:IDRA): Our members Bought at $2.3, Up 20% In Just 24 Hours (NASDAQ:IDRA) www.marketnewscall.com - September 21 at 9:45 AM
	ETF’s with exposure to Idera Pharmaceuticals, Inc. : September 20, 2016 (NASDAQ:IDRA) www.capitalcube.com - September 20 at 10:42 AM
	Stock Update, a Closer Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 15 at 5:55 PM
	Keen Investors Narrowing Their Focus on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 15 at 8:45 AM
	Getting a Closer Look at Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 12 at 5:25 PM
	Stock Tracker: Earnings & Estimates for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Frisco Fastball (NASDAQ:IDRA) friscofastball.com - September 11 at 9:51 AM
	Focusing the Spotlight on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 9 at 10:18 AM
	ETF’s with exposure to Idera Pharmaceuticals, Inc. : September 8, 2016 (NASDAQ:IDRA) www.capitalcube.com - September 8 at 5:28 PM
	A Second Look at Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - September 2 at 5:32 PM
	HC Stocks News Ring - Sequenom, Inc. (NASDAQ:SQNM), Idera ... - share market updates (press release) (NASDAQ:IDRA) sharemarketupdates.com - September 2 at 5:32 PM
	Wedbush Positive on Idera Pharmaceuticals Inc (IDRA); Sings the Praises of 3GA Technology - Smarter Analyst (NASDAQ:IDRA) www.smarteranalyst.com - August 26 at 5:25 PM
	ETF’s with exposure to Idera Pharmaceuticals, Inc. : August 26, 2016 (NASDAQ:IDRA) www.capitalcube.com - August 26 at 5:25 PM
	Looking Closer at Stocks of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - August 24 at 5:28 PM
	7:03 am Idera Pharma presents new pre-clinical data 'that demonstrates the novel gene-silencing mechanism of action of the third generation antisense technology platform' (NASDAQ:IDRA) finance.yahoo.com - August 24 at 8:39 AM
	Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology (NASDAQ:IDRA) www.publicnow.com - August 24 at 8:39 AM
	Small Cap Insight on Shares of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - August 20 at 5:25 PM
	Crowd Perspectives & Analyst Views on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)? - Post News (NASDAQ:IDRA) www.kentuckypostnews.com - August 20 at 9:46 AM
	Earnings in Perspective for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Post News (NASDAQ:IDRA) www.kentuckypostnews.com - August 19 at 5:32 PM
	Penny Stock Alert - Update & Review on This Stock: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - August 19 at 5:32 PM
	Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Hit $6 Price Target? - Investor Newswire (NASDAQ:IDRA) www.investornewswire.com - August 19 at 5:32 PM
	Morning Alert: Idera Pharmaceuticals (NASDAQ:IDRA), Allot ... - KC Register (NASDAQ:IDRA) www.kcregister.com - August 18 at 5:35 PM
	Taking A Closer Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - August 18 at 8:35 AM
	Small Cap Update on: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - August 16 at 5:46 PM
	A Closer Look at Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Duncan Research (NASDAQ:IDRA) www.duncanindependent.com - August 16 at 5:46 PM
	Idera to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:IDRA) finance.yahoo.com - August 12 at 5:38 PM
	ETF’s with exposure to Idera Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:IDRA) www.capitalcube.com - August 12 at 5:38 PM
	Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:IDRA) www.capitalcube.com - August 11 at 5:49 PM
	Analyst's Notable Buzzers: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) , Emergent Biosolutions, Inc. (NYSE:EBS) - Street Updates (NASDAQ:IDRA) www.streetupdates.com - August 10 at 8:25 AM